Elexacaftor–tezacaftor–ivacaftor decreases pseudomonas abundance in the sinonasal microbiome in cystic fibrosis

Abstract excerpt

BACKGROUND: Chronic rhinosinusitis (CRS) is common in individuals with cystic fibrosis (CF) and is marked by chronic inflammation and episodes of infection that negatively impact quality of life. Several studies have shown that elexacaftor-tezacaftor-ivacaftor (ETI) improves symptoms and examination findings in CF-CRS. The current study determines the effect of ETI on the sinonasal microbiota in CF. METHODS:...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cystic Fibrosis Research Advances
• Share to Head and Neck Surgical Oncology
• Share to Sinusitis and nasal conditions